Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies
Table 1
Characteristics of CLL cohort.
Rai stage
0
I
II
III
IV
Total
Patients’ number
14
8
14
15
8
59
IgVH mutated/unmutated/NA
10/1/3
3/2/3
3/9/2
1/9/5
3/3/2
20/24/15
TP53 mutated/unmutated/NA
0/6/8
0/5/3
0/12/2
1/8/6
0/5/3
1/36/22
Normal karyotype
3
0
1
5
1
10
13q deletion
7
1
4
3
0
15
12 trisomy
0
1
2
4
3
10
11q deletion
0
2
2
1
2
7
17p deletion
0
0
1
0
0
1
Other karyotype changes
1
3
4
2
1
11
No cytogenetics available
3
1
0
0
1
5
Sinusitis
0
0
2
0
0
2
Bronchitis
2
0
0
0
0
2
Pneumonia
0
0
1
0
1
2
Other bacterial infection requiring ATB therapy
2
1
1
2
2
8
Hospitalisation due to infection
0
0
1
1
1
3
IgVH: immunoglobulin heavy chain variable region gene; TP53: tumour protein 53; NA: data not available. Only prognostically worst karyotype change is recorded; all infections were recorded in the period of one year before blood sample collection.
